Literature DB >> 17979166

Light activation of anti-CD3 in vivo reduces the growth of an aggressive ovarian carcinoma.

Stephen Thompson1, Robert Stewart, Jacqueline A Smith, Colin H Self.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17979166     DOI： 10.1002/cmdc.200700116

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  3 in total

1.  Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.

Authors:  Stephen Thompson; John Dessi; Colin H Self
Journal:  MAbs       Date:  2009-07-19       Impact factor: 5.857

2.  Chronic activation of the D156A point mutant of Channelrhodopsin-2 signals apoptotic cell death: the good and the bad.

Authors:  Michael Perny; Lukas Muri; Heather Dawson; Sonja Kleinlogel
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469

Review 3.  The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control.

Authors:  Roberta Lucchi; Jordi Bentanachs; Benjamí Oller-Salvia
Journal:  ACS Cent Sci       Date:  2021-04-26       Impact factor: 14.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.